Nathan L. Mata sold $154k of BLTE
Chief Scientific Officer at BELITE BIO, INC. 1,000 shares at an average of $153.84, traded May 6, 2026, filed May 7, 2026.
Score components
- +15RoleOfficer
- +11Trade size$154k at market
- +20Share of holdings soldSold 60% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.1%, 3m +3.0%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-211974, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 6, 2026 | SOpen-market sale American depositary share10b5-1 | -8 | $151.57 | $1,213 | 1,658 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale American depositary share10b5-1 | -424 | $152.67 | $65k | 1,234 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale American depositary share10b5-1 | -128 | $153.42 | $20k | 1,106 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale American depositary share10b5-1 | -240 | $154.41 | $37k | 866 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale American depositary share10b5-1 | -100 | $155.97 | $16k | 766 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale American depositary share10b5-1 | -100 | $156.00 | $16k | 666 | May 7, 2026 |
Related signals
Other insiders at BELITE BIO, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 4Weak | BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $83k 500 shares | -3% | |
| 55Moderate | BELITE BIO, INC | Hao-Yuan Chuang Chief Financial Officer | $13M 67,395 shares | -72% | |
| 58Moderate | BELITE BIO, INC | Yu-Hsin Lin Chief Executive Officer | $19M 100,435 shares | -59% | |
| 50Moderate | BLTEsell BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $1.5M 10,000 shares | -40% | |
| 50Moderate | BLTEsell BELITE BIO, INC | Hendrik Peter Scholl Chief Medical Officer | $1.4M 10,000 shares | -29% | |
| 25Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $102k 666 shares | -100% | |
| 16Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $156k 1,000 shares | -38% | |
| 16Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $156k 1,000 shares | -27% | |
| 11Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $156k 1,000 shares | -21% | |
| 11Weak | BELITE BIO, INC | Nathan L. Mata Chief Scientific Officer | $157k 1,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.